Trial reportScientific reports2026
A nurse navigator program for the management of hepatitis C virus in patients with severe mental disorder. A feasibility trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
People with severe mental disorders (SMD) face higher hepatitis C virus (HCV) infection risks and lower treatment adherence compared to the general population. Traditional care pathways often fail due to fragmented coordination and patient-related barriers. This study evaluates the feasibility and acceptability of an individualized nurse navigation program (NNP) designed to facilitate adherence to medical appointments and pharmacological treatment in this population. A feasibility randomized open parallel trial was conducted. The intervention simplified the clinical pathway through intensive nursing support (phone reminders, in-person meetings, home visits) and appointment accompaniment. Primary outcomes included recruitment, retention, refusal rates, cure rate defined as undetectable HCV RNA at 12 weeks post-treatment, and identification of barriers. From 1,916 assessed individuals, 20 were eligible and 13 finally randomized (65% participation, refusal rate 35%). Overall, 69% (9/13) achieved a cure. Notably, the average cure time was nearly 11 months, indicating that standard 6-month follow-up is insufficient. Key facilitators included institutional residency and competent caregivers, while barriers included symptom-related non-attendance and system-level delays, such as deferred treatment prescription by gastroenterologists. The NNP is feasible and enhances HCV outcomes in SMD populations. Definitive trials require extended follow-up periods of 24 months and larger multicenter samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.